तुलना करने के लिए मीट्रिक्स | TRVN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTRVNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −7.7x | −0.4x | |
PEG अनुपात | 0.00 | −0.04 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 7.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 102.2% | 48.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.0% | 5.8% | अनलॉक करें |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.